Levobetaxolol

Levobetaxolol
Systematic (IUPAC) name


(S)-1-[p-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	topical (ophthalmic)
Pharmacokinetic data
Biological half-life	20 hours
Identifiers
CAS Number	93221-48-8^N
ATC code	None
PubChem	CID 60657
IUPHAR/BPS	8035
ChemSpider	54669^Y
UNII	75O9XHA4TU^Y
ChEBI	CHEBI:59254^Y
ChEMBL	CHEMBL1201274^N
Chemical data
Formula	C₁₈H₂₉NO₃
Molar mass	307.427 g/mol
SMILES O(CCc1ccc(OC[C@@H](O)CNC(C)C)cc1)CC2CC2
InChI InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1^Y Key:NWIUTZDMDHAVTP-KRWDZBQOSA-N^Y
^NY (what is this?) (verify)

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is typically marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).

Effect

Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It is indicated for IOP reduction in patients with open-angle glaucoma or ocular hypertension. Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

Contraindications and side effects

Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure.

The drug has been associated with bradycardia and hypertension.

Beta blockers (C07)

β, non-selective	Alprenolol Bopindolol Bupranolol Carteolol Cloranolol Mepindolol Nadolol Oxprenolol Penbutolol Pindolol/Iodopindolol Propranolol Sotalol Tertatolol Timolol

β₁-selective	Acebutolol Atenolol Betaxolol Bevantolol Bisoprolol Celiprolol Epanolol Esmolol Metoprolol Nebivolol Practolol S-Atenolol Talinolol

β₂-selective	Butaxamine

α₁- + β-selective	Carvedilol Labetalol

^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Drugs used for glaucoma preparations and miosis (S01E)

Sympathomimetics

Parasympathomimetics

muscarinic	Aceclidine Pilocarpine

muscarinic/nicotinic	Acetylcholine Carbachol

Acetylcholinesterase inhibitors	Demecarium Ecothiopate Stigmine (Fluostigmine Neostigmine Physostigmine) Paraoxon

Carbonic anhydrase inhibitors/
(sulfonamides)

Beta blocking agents

Prostaglandin analogues (F_2α)

Other agents

This article is issued from Wikipedia - version of the Tuesday, June 16, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.